Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
Phase 2 Terminated
1 enrolled 7 charts
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Phase 1/2 Terminated
8 enrolled 8 charts
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Phase 2 Terminated
9 enrolled 11 charts
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
Phase 2 Terminated
8 enrolled 8 charts
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
Phase 2 Terminated
1 enrolled 9 charts
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer
Phase 2 Terminated
5 enrolled 10 charts
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
Phase 2 Terminated
27 enrolled 13 charts
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Phase 2 Terminated
5 enrolled 7 charts
BMT CTN 0901
Phase 3 Terminated
272 enrolled 29 charts
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Phase 1 Terminated
6 enrolled 11 charts
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
Phase 2 Terminated
20 enrolled 7 charts
DMV
Phase 1/2 Terminated
13 enrolled 8 charts
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
Phase 1/2 Terminated
8 enrolled 11 charts
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
Phase 2 Terminated
90 enrolled 14 charts
BMT-02
Phase 1 Terminated
3 enrolled 5 charts
Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma
Phase 2/3 Terminated
3 enrolled 4 charts
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Phase 1/2 Terminated
3 enrolled 15 charts
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Phase 1/2 Terminated
1 enrolled 8 charts
VelRand
Phase 3 Terminated
3 enrolled 11 charts
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
Phase NA Terminated
3 enrolled 7 charts
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
Phase 2 Terminated
2 enrolled 5 charts
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Phase 1/2 Terminated
10 enrolled 13 charts
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
Phase 2 Terminated
24 enrolled 17 charts
Stem Cell Transplantation for Hematological Malignancies
Phase 2/3 Terminated
11 enrolled 12 charts
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
Phase 2 Terminated
8 enrolled 6 charts
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
Phase 2 Terminated
19 enrolled 7 charts
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
Phase 2 Terminated
12 enrolled 12 charts
HD Melphalan and SCT in Patients With IGDD or LCDD
Phase 2 Terminated
5 enrolled 7 charts
Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma
Phase 2 Terminated
1 enrolled 11 charts
Cord Blood Transplantation for Patients With Cancer
Phase 2 Terminated
1 enrolled 4 charts
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 1/2 Terminated
3 enrolled 5 charts
V-BEAM
Phase 2 Terminated
10 enrolled 16 charts
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
Phase 2 Terminated
13 enrolled 5 charts
Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Phase 2 Terminated
40 enrolled 2 charts
Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor
Phase 2 Terminated
5 enrolled 4 charts
Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study
Phase 1/2 Terminated
39 enrolled 9 charts
S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma
Phase 2 Terminated
1 enrolled 6 charts
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
Phase 2 Terminated
5 enrolled 5 charts
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
Phase 2 Terminated
27 enrolled 5 charts
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
Phase 3 Terminated
5 enrolled 6 charts